Flecainide as first-line treatment for supraventricular tachycardia in newborns

Marco Ferlini, Anna M. Colli, Carla Bonanomi, Laura Salvini, Maria A. Galli, Patrizia Salice, Romana Ravaglia, Marco Centola, Gian B. Danzi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

BACKGROUND: Flecainide for the treatment of supraventricular tachycardia (SVT) in newborns is still controversial because of its potentially severe proarrhythmic effects. METHODS AND RESULTS: Between January 2004 and December 2006, we used flecainide to treat 20 consecutive newborns (15 males) with paroxysmal SVT without any structural heart disease. Their age at hospitalization was 11.5 ± 11.1 days. The intravenous administration of flecainide (1 mg/kg) effectively restored sinus rhythm in all the patients. Once stable sinus rhythm had been restored, the drug was administered orally at a dose of 2 mg/kg/day twice daily, which was uptitrated as the patients gained weight. The patients were followed up for up to 24 months with clinical evaluations, baseline ECG and 24-h Holter monitoring every 3 months. There were neither deaths nor any episodes of heart failure or sustained ventricular tachycardia during follow-up. SVT were completely controlled in 17 patients (85%), with an oral dose of 3.35 ± 1.35 mg/kg/day of flecainide; in the remaining three patients with refractory arrhythmias, propranolol was added for optimal treatment. No significant increase in the duration of QRS (70 ± 1.09 vs. 63.8 ± 1.87 ms, P = NS) or any significant QTc prolongation (413 ± 7.4 vs. 412.6 ± 8.01 ms, P = NS) was observed. One patient developed an incomplete right bundle branch block promptly reverted by reducing the dose. CONCLUSION: This preliminary experience indicates that flecainide is well tolerated and effective as first-line treatment for paroxysmal SVT in newborns without structural heart disease.

Original languageEnglish
Pages (from-to)372-375
Number of pages4
JournalJournal of Cardiovascular Medicine
Volume10
Issue number5
DOIs
Publication statusPublished - May 2009

Fingerprint

Flecainide
Supraventricular Tachycardia
Newborn Infant
Paroxysmal Tachycardia
Heart Diseases
Therapeutics
Ambulatory Electrocardiography
Bundle-Branch Block
Ventricular Tachycardia
Propranolol
Intravenous Administration
Cardiac Arrhythmias
Electrocardiography
Hospitalization
Heart Failure
Weights and Measures
Pharmaceutical Preparations

Keywords

  • Antiarrhythmia agents
  • Arrhythmia
  • Pediatrics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Flecainide as first-line treatment for supraventricular tachycardia in newborns. / Ferlini, Marco; Colli, Anna M.; Bonanomi, Carla; Salvini, Laura; Galli, Maria A.; Salice, Patrizia; Ravaglia, Romana; Centola, Marco; Danzi, Gian B.

In: Journal of Cardiovascular Medicine, Vol. 10, No. 5, 05.2009, p. 372-375.

Research output: Contribution to journalArticle

Ferlini, M, Colli, AM, Bonanomi, C, Salvini, L, Galli, MA, Salice, P, Ravaglia, R, Centola, M & Danzi, GB 2009, 'Flecainide as first-line treatment for supraventricular tachycardia in newborns', Journal of Cardiovascular Medicine, vol. 10, no. 5, pp. 372-375. https://doi.org/10.2459/JCM.0b013e328329154d
Ferlini, Marco ; Colli, Anna M. ; Bonanomi, Carla ; Salvini, Laura ; Galli, Maria A. ; Salice, Patrizia ; Ravaglia, Romana ; Centola, Marco ; Danzi, Gian B. / Flecainide as first-line treatment for supraventricular tachycardia in newborns. In: Journal of Cardiovascular Medicine. 2009 ; Vol. 10, No. 5. pp. 372-375.
@article{779148c18607458494c7e691d1f79b10,
title = "Flecainide as first-line treatment for supraventricular tachycardia in newborns",
abstract = "BACKGROUND: Flecainide for the treatment of supraventricular tachycardia (SVT) in newborns is still controversial because of its potentially severe proarrhythmic effects. METHODS AND RESULTS: Between January 2004 and December 2006, we used flecainide to treat 20 consecutive newborns (15 males) with paroxysmal SVT without any structural heart disease. Their age at hospitalization was 11.5 ± 11.1 days. The intravenous administration of flecainide (1 mg/kg) effectively restored sinus rhythm in all the patients. Once stable sinus rhythm had been restored, the drug was administered orally at a dose of 2 mg/kg/day twice daily, which was uptitrated as the patients gained weight. The patients were followed up for up to 24 months with clinical evaluations, baseline ECG and 24-h Holter monitoring every 3 months. There were neither deaths nor any episodes of heart failure or sustained ventricular tachycardia during follow-up. SVT were completely controlled in 17 patients (85{\%}), with an oral dose of 3.35 ± 1.35 mg/kg/day of flecainide; in the remaining three patients with refractory arrhythmias, propranolol was added for optimal treatment. No significant increase in the duration of QRS (70 ± 1.09 vs. 63.8 ± 1.87 ms, P = NS) or any significant QTc prolongation (413 ± 7.4 vs. 412.6 ± 8.01 ms, P = NS) was observed. One patient developed an incomplete right bundle branch block promptly reverted by reducing the dose. CONCLUSION: This preliminary experience indicates that flecainide is well tolerated and effective as first-line treatment for paroxysmal SVT in newborns without structural heart disease.",
keywords = "Antiarrhythmia agents, Arrhythmia, Pediatrics",
author = "Marco Ferlini and Colli, {Anna M.} and Carla Bonanomi and Laura Salvini and Galli, {Maria A.} and Patrizia Salice and Romana Ravaglia and Marco Centola and Danzi, {Gian B.}",
year = "2009",
month = "5",
doi = "10.2459/JCM.0b013e328329154d",
language = "English",
volume = "10",
pages = "372--375",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Flecainide as first-line treatment for supraventricular tachycardia in newborns

AU - Ferlini, Marco

AU - Colli, Anna M.

AU - Bonanomi, Carla

AU - Salvini, Laura

AU - Galli, Maria A.

AU - Salice, Patrizia

AU - Ravaglia, Romana

AU - Centola, Marco

AU - Danzi, Gian B.

PY - 2009/5

Y1 - 2009/5

N2 - BACKGROUND: Flecainide for the treatment of supraventricular tachycardia (SVT) in newborns is still controversial because of its potentially severe proarrhythmic effects. METHODS AND RESULTS: Between January 2004 and December 2006, we used flecainide to treat 20 consecutive newborns (15 males) with paroxysmal SVT without any structural heart disease. Their age at hospitalization was 11.5 ± 11.1 days. The intravenous administration of flecainide (1 mg/kg) effectively restored sinus rhythm in all the patients. Once stable sinus rhythm had been restored, the drug was administered orally at a dose of 2 mg/kg/day twice daily, which was uptitrated as the patients gained weight. The patients were followed up for up to 24 months with clinical evaluations, baseline ECG and 24-h Holter monitoring every 3 months. There were neither deaths nor any episodes of heart failure or sustained ventricular tachycardia during follow-up. SVT were completely controlled in 17 patients (85%), with an oral dose of 3.35 ± 1.35 mg/kg/day of flecainide; in the remaining three patients with refractory arrhythmias, propranolol was added for optimal treatment. No significant increase in the duration of QRS (70 ± 1.09 vs. 63.8 ± 1.87 ms, P = NS) or any significant QTc prolongation (413 ± 7.4 vs. 412.6 ± 8.01 ms, P = NS) was observed. One patient developed an incomplete right bundle branch block promptly reverted by reducing the dose. CONCLUSION: This preliminary experience indicates that flecainide is well tolerated and effective as first-line treatment for paroxysmal SVT in newborns without structural heart disease.

AB - BACKGROUND: Flecainide for the treatment of supraventricular tachycardia (SVT) in newborns is still controversial because of its potentially severe proarrhythmic effects. METHODS AND RESULTS: Between January 2004 and December 2006, we used flecainide to treat 20 consecutive newborns (15 males) with paroxysmal SVT without any structural heart disease. Their age at hospitalization was 11.5 ± 11.1 days. The intravenous administration of flecainide (1 mg/kg) effectively restored sinus rhythm in all the patients. Once stable sinus rhythm had been restored, the drug was administered orally at a dose of 2 mg/kg/day twice daily, which was uptitrated as the patients gained weight. The patients were followed up for up to 24 months with clinical evaluations, baseline ECG and 24-h Holter monitoring every 3 months. There were neither deaths nor any episodes of heart failure or sustained ventricular tachycardia during follow-up. SVT were completely controlled in 17 patients (85%), with an oral dose of 3.35 ± 1.35 mg/kg/day of flecainide; in the remaining three patients with refractory arrhythmias, propranolol was added for optimal treatment. No significant increase in the duration of QRS (70 ± 1.09 vs. 63.8 ± 1.87 ms, P = NS) or any significant QTc prolongation (413 ± 7.4 vs. 412.6 ± 8.01 ms, P = NS) was observed. One patient developed an incomplete right bundle branch block promptly reverted by reducing the dose. CONCLUSION: This preliminary experience indicates that flecainide is well tolerated and effective as first-line treatment for paroxysmal SVT in newborns without structural heart disease.

KW - Antiarrhythmia agents

KW - Arrhythmia

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=66349113447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349113447&partnerID=8YFLogxK

U2 - 10.2459/JCM.0b013e328329154d

DO - 10.2459/JCM.0b013e328329154d

M3 - Article

C2 - 19300276

AN - SCOPUS:66349113447

VL - 10

SP - 372

EP - 375

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 5

ER -